Over the past decade, our understanding of HIV infection and the development of highly active antiretroviral therapy (HAART) regimens has substantially increased the life expectancy of HIV type-1 (HIV-1)-infected individuals [1] . Among the antiretroviral (ARV) agents currently available, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) are extensively used because of their demonstrated efficacy, safety profile and convenience [2] [3] [4] [5] . Efavirenz is one of the recommended agents for first-line therapy in treatment-naive patients [2] [3] [4] [5] ; however, the development of cross-resistance between the first-generation NNRTIs efavirenz and nevirapine has limited their use in treatment-experienced adult patients [6, 7]. In addition, although efavirenz and nevirapine are generally well-tolerated, efavirenz can be associated with neuropsychiatric adverse events (AEs) and both drugs can be associated with hepatic and rash-related AEs and lipid abnormalities [8,9]. Efavirenz is also associated with teratogenicity [8]; therefore, a clinical need exists for the development of next-generation NNRTIs with more favourable resistance and tolerability profiles for use in a broad patient population.
Over the past decade, our understanding of HIV infection and the development of highly active antiretroviral therapy (HAART) regimens has substantially increased the life expectancy of HIV type-1 (HIV-1)-infected individuals [1] . Among the antiretroviral (ARV) agents currently available, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) are extensively used because of their demonstrated efficacy, safety profile and convenience [2] [3] [4] [5] . Efavirenz is one of the recommended agents for first-line therapy in treatment-naive patients [2] [3] [4] [5] ; however, the development of cross-resistance between the first-generation NNRTIs efavirenz and nevirapine has limited their use in treatment-experienced adult patients [6, 7] . In addition, although efavirenz and nevirapine are generally well-tolerated, efavirenz can be associated with neuropsychiatric adverse events (AEs) and both drugs can be associated with hepatic and rash-related AEs and lipid abnormalities [8, 9] . Efavirenz is also associated with teratogenicity [8] ; therefore, a clinical need exists for the development of next-generation NNRTIs with more favourable resistance and tolerability profiles for use in a broad patient population.
Development of etravirine
For several years, the most commonly used regimens for treatment-experienced adult patients have been primarily based on protease inhibitors (PIs), usually in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The fusion inhibitor enfuvirtide has proven beneficial in highly treatment-experienced patients who have exhausted other ARV options. The choice of ARV agents for treatment-experienced adult patients has recently been broadened by the development of potent PIs such as darunavir, the integrase strand transfer inhibitor raltegravir, and the chemokine receptor 5 antagonist maraviroc.
Etravirine (TMC125) was developed to meet the need for an NNRTI with a low propensity to the development of resistance that also maintains the efficacy and improves on the safety of the NNRTI class [10] .
Introduction
Etravirine is a di-aryl-pyrimidine derivative, developed by optimization of a series of di-aryl-pyrimidine compounds through evaluation of in vitro activity against NNRTI-resistant HIV-1 strains [11, 12] . Selected for clinical development following initial in vitro investigations [11, 12] , this next-generation NNRTI has demonstrated potent and sustained ARV activity against HIV-1 in treatment-experienced adult patients in large Phase III trials. Etravirine is approved for use as part of HAART regimens in the treatment of HIV-1 infection in treatment-experienced adult patients, including those with NNRTI resistance [13, 14] . Prior to the introduction of etravirine, it was generally not possible to sequentially use NNRTIs in patients following failure of their first NNRTI-based regimen.
Mechanism of action of etravirine
NNRTIs target HIV-1 reverse transcriptase by binding to a narrow hydrophobic pocket close to the active site of the enzyme and consequently inhibiting enzymatic function. With the first-generation NNRTIs efavirenz and nevirapine, a single mutation in the gene coding for the HIV-1 reverse transcriptase enzyme is sufficient to inhibit the binding of the ARV agent to the enzyme. This can lead to >100-fold reductions in susceptibility and ultimately promotes cross-resistance to other NNRTIs. By contrast, etravirine displays a high degree of molecular flexibility, with a capacity for rotation and reorientation that allows binding in the hydrophobic pocket, even in the presence of mutations capable of conferring resistance to first-generation NNRTIs [15] . Consequently, etravirine has a higher genetic barrier to the development of resistance than first-generation NNRTIs [15, 16] .
Etravirine clinical development programme and formulation development
Following the assessment of etravirine in single and multiple dose Phase I studies in healthy volunteers and in proof-of-concept trials, etravirine has been evaluated extensively in large Phase IIb and Phase III clinical trials in HIV-1-infected, treatment-experienced adult patients.
Clinical efficacy and safety/tolerability were initially evaluated in two Phase IIb studies, TMC125-C203 [17] and TMC125-C223 [18, 19] . Preliminary efficacy results from TMC125-C203 assisted with the design of TMC125-C223, and results of both studies led to the selection of an etravirine dose of 800 mg twice daily for Phase III development. However, as the use of this Phase II formulation of etravirine would have resulted in patients taking four 200 mg tablets twice daily to achieve the 800 mg twice daily dosage, a new formulation was developed for Phase III trials [20] , and this dosage was subsequently used in the early access programme. The improved bioavailability of the novel formulation resulted in increased systemic exposure to etravirine, such that patients were able to take 200 mg etravirine (as two 100 mg tablets) twice daily while retaining similar exposure to that of the 800 mg twice daily Phase II formulation. The clinical development programme included the identically designed, randomized, double-blinded, placebo-controlled, Phase III DUET-1 (TMC125-C206) and DUET-2 (TMC125-C216) trials.
Efficacy of etravirine
Phase IIb trials TMC125-C203 was a randomized, double-blinded, placebo-controlled dose-escalation trial to determine the safety and tolerability of etravirine at doses of 400 mg, 800 mg and 1,200 mg twice daily (Phase II formulation), plus an optimized background regimen (BR) containing at least two active ARVs. The results of this trial showed that etravirine was generally safe and welltolerated up to doses of 1,200 mg twice daily, with no statistically significant differences observed between the etravirine and placebo groups in the overall incidence and severity of AEs [17] .
The randomized TMC125-C223 trial compared the efficacy and safety of 400 mg and 800 mg etravirine twice daily (Phase II formulation) plus a BR (NRTIs and/or lopinavir/ritonavir and/or enfuvirtide) with a standard-of-care regimen (NRTIs and/or PIs, and/or enfuvirtide) in treatment-experienced adult patients. The BR included at least two approved ARVs. Results showed that patients treated with 400 mg and 800 mg etravirine twice daily displayed a statistically significant mean change in HIV-1 RNA viral load from baseline at week 48 (P=0.018 and P=0.002 for 400 mg and 800 mg etravirine, respectively) [19] . If only one active ARV was used in the underlying therapy, then an added benefit of etravirine 800 mg twice daily compared with etravirine 400 mg twice daily was observed, favouring the 800 mg twice daily dose in this population. In addition, there were no dose-related differences in the safety and tolerability profile of etravirine [19] .
Based on the dose-finding data obtained from TMC125-C223, the exploratory TMC125-C227 trial was conducted to assess the efficacy and safety of etravirine versus a PI in HIV-1-infected, PI-naive adults who had previously failed treatment with NNRTIs [21] . Eligible patients received either 800 mg etravirine twice daily or an investigator-selected control PI (ritonavirboosted or unboosted), both combined with a BR of two NRTIs. Patients enrolled generally had high levels of both NRTI and NNRTI resistance. An unplanned interim analysis of this trial showed that etravirinetreated patients, although exhibiting a substantial initial decrease in viral load, displayed inferior virological responses compared with patients receiving a PI-based regimen [21] . As a result, etravirine treatment was halted. The high levels of NRTI and NNRTI resistance at baseline and the recycling of NRTIs because of a lack of other options were considered to be the most probable explanations for the suboptimal virological responses in the PI-naive patients treated with etravirine and NRTIs when compared with the PI-based regimen. The results from this trial demonstrated that, if the backbone only consisted of two NRTIs, a PI was a better choice in achieving virological suppression in PI-naive patients with first-line virological failure on an NNRTI-based regimen [21] .
Consistent with current guidelines [3, 4] , the TMC125-C227 trial results showed that patients who experience virological failure on an NNRTI-based regimen have to rapidly switch treatment to minimize the accumulation of resistance-associated mutations (RAMs) and maximize future treatment options. Results also indicate that etravirine, similar to all ARVs, should be used as part of a regimen with other active agents to ensure optimal efficacy in treatment-experienced adult patients.
Phase III DUET trials
DUET-1 and DUET-2 were randomized, doubleblinded, placebo-controlled, 48-week Phase III clinical trials that enrolled treatment-experienced patients with HIV-1 infection. DUET-1 and DUET-2 assessed the efficacy, tolerability and safety of etravirine compared with placebo when given with a background ARV regimen. The trials were identical in design, differing only in their geographical location (DUET-1 was conducted in Thailand, Europe and the Americas, whereas DUET-2 was conducted in Europe, Australia, Canada and the US) and had a 48-week optional extension period. Patients with at least one documented NNRTI RAM, at least three primary PI mutations and a plasma viral load >5,000 HIV-1 RNA copies/ml were treated with either 200 mg etravirine or placebo twice daily, plus a BR (darunavir/ritonavir 600/100 mg twice daily, investigator-selected NRTIs and optional enfuvirtide) [22, 23] . The primary end point was the proportion of patients with a confirmed plasma viral load <50 HIV-1 RNA copies/ml (intent-to-treat, time-to-loss of virological response [ITT-TLOVR]) at week 24.
Separate analyses of efficacy and safety in DUET-1 and DUET-2 have been conducted at 24 and 48 weeks [22] [23] [24] [25] and pre-specified pooled analyses have also been completed [26, 27] . These pooled analyses allowed for a more comprehensive and rigorous assessment of etravirine efficacy because of the larger and more robust dataset. The greater statistical power of this larger patient population compared with the individual trials also allowed a number of subgroup analyses to be performed [27] . Pooled baseline characteristics and week 48 efficacy results from the DUET trials are described below.
In total, 599 patients received etravirine and 604 patients received placebo, both in combination with a BR as described above. Baseline characteristics were comparable between treatment groups, with a median baseline plasma viral load of 4.8 log 10 HIV-1 RNA copies/ml in both groups and a median baseline CD4 + T-cell count of 99 and 109 cells/mm 3 in the etravirine and placebo groups, respectively [27] . Overall enfuvirtide use, baseline darunavir and NRTI sensitivity, and the number of active agents in the BR were also comparable between treatment arms [22, 23, 27] .
After 48 weeks of treatment, significantly more patients in the etravirine group achieved a confirmed plasma viral load <50 HIV-1 RNA copies/ml than in the placebo group (60.6% versus 39.7%; ITT-TLOVR analysis, P<0.0001; Table 1 and Figure 1 ). The durability of the etravirine response was reflected in the proportion of patients with sustained virological suppression from week 24 to week 48 -92.0% of patients in the etravirine group who achieved <50 HIV-1 RNA copies/ml at week 24 maintained virological suppression through to week 48 [27] . As would be expected, virological response increased with more active agents in the BR.
Overall, virological response was higher in the etravirine group than the placebo group irrespective of enfuvirtide use or number of active background ARVs. Depending on the number of additional background active agents, 71-91% of patients infected with virus fully sensitive to etravirine (etravirine fold change in 50% effective concentration [FC] values ≤3) and with virus fully sensitive to darunavir (darunavir FC≤10) in the BR achieved viral suppression to <50 HIV-1 RNA copies/ml [28] . Additionally, in patients infected with virus fully sensitive to etravirine and at least two active agents in the BR (NRTIs, darunavir or enfuvirtide), a response rate of 82% was observed ( Figure 2 ). These response rates observed in patients with virus fully sensitive to etravirine in DUET are similar to those that have been reported with ARV regimens in treatmentnaive patients [29, 30] .
In DUET, etravirine-treated patients consistently achieved higher virological response rates than those in the placebo group, irrespective of race, baseline disease characteristics, previous NNRTI use or pharmacokinetic exposure [31, 32] . Predictors of virological response in both treatment groups were baseline plasma HIV-1 RNA viral load, baseline CD4 + T-cell count, enfuvirtide use and number of active background ARVs (using the phenotypic susceptibility score), although etravirine provided added clinical benefit over placebo in each subgroup [31, 32] .
The favourable ARV activity of etravirine observed at 48 weeks in DUET was paralleled by a significantly higher increase in mean CD4 + T-cell count from baseline versus placebo (98.2 versus 72.9 cells/mm 3 for etravirine and placebo, respectively; P=0.0006) [27] .
Although cross-study comparisons are inherently associated with limitations, it is encouraging that the virological benefits observed with etravirine in DUET are similar to those seen with other recently introduced agents investigated in comparable populations of treatment-experienced patients. This is apparent when the proportion of patients achieving plasma viral load <50 HIV-1 RNA copies/ml at 48 weeks in the etravirine arm of DUET (60.6%) is compared across the active regimen arm of BENCHMRK-1 and -2 (raltegravir, 62.1%), MOTIVATE 1 (maraviroc twice daily, 46.4%), MOTIVATE 2 (maraviroc twice daily, 44.5%), POWER 1 and 2 (darunavir/ritonavir, 45.5%) and RESIST-1 and -2 (tipranavir/ritonavir, 22.7%) clinical trials [33] [34] [35] [36] . Notably, a recent analysis indirectly comparing etravirine and raltegravir showed that the two agents demonstrate a similar treatment effect when differences in BR are taken into account [37] . The mean odds ratios for both etravirine and raltegravir were shown to be >1, indicating that both treatments increase the probability of attaining a significantly higher number of patients with viral load <50 HIV-1 RNA copies/ml compared with placebo. When the results were adjusted for use of darunavir/ritonavir in the BR, the predicted effects of both raltegravir and etravirine were found to be similar [37] .
In addition to providing virological suppression and improved immune responses, the ability to improve clinical outcome and reduce morbidity and mortality is an important and sought-after feature of any new drug. In the DUET 48-week analysis, the proportion of patients reaching a clinical end point (a new AIDS-defining illness or death) was significantly lower for patients in the etravirine group compared with those in the placebo group (5.8% versus 9.8%; P=0.0408) [27] . Similarly, significantly fewer patients in the etravirine group versus the placebo group were hospitalized through week 48 (17.5% versus 23.0%; P=0.0006) [24, 25] . 
Efficacy combined with novel agents
For multi-ARV-experienced patients, etravirine is likely to be used in combination with other ARVs, including agents from novel classes (for example, raltegravir or maraviroc) [2] . The efficacy of etravirine combined with raltegravir and darunavir/ritonavir was assessed in patients with extensive baseline resistance (≥3 primary PI mutations, ≥3 NRTI mutations, ≤3 darunavir RAMs and ≤3 NNRTI mutations) in the single-arm, Phase II TRIO trial [38] . In this trial, substantial ARV activity was achieved with the combination of etravirine, darunavir and raltegravir plus a physician-selected optimized BR (composed of NRTIs and/or enfuvirtide). At 24 weeks, 90% of these treatment-experienced patients achieved a plasma viral load <50 HIV-1 RNA copies/ml, which was maintained through 48 weeks (86% achieved <50 HIV-1 RNA copies/ml) [38] . Virological responses obtained in TRIO have not been exceeded in this patient population by alternative ARV regimens either on the market or in clinical development. Access to etravirine in treatment-experienced patients with limited treatment options has also been provided via the early access programme. In this clinical programme, etravirine was combined with a variety of other physician-selected ARVs. In a subanalysis of patients receiving etravirine, raltegravir and darunavir, 70% achieved plasma viral load <50 HIV-1 RNA copies/ml at week 24 [39] . The efficacy of etravirine in combination with novel agents is currently under investigation [38, 40] .
Safety and tolerability of etravirine
For any class of ARV agents, the development of AEs is one of the most common reasons for switching or discontinuing therapy and non-adherence to medication. It is, therefore, important to discuss the safety and tolerability of etravirine and to assess its tolerability profile relative to other ARVs, particularly in treatment-experienced patients where the occurrence of AEs can greatly affect quality of life. Throughout its clinical development, etravirine has generally demonstrated a favourable safety and tolerability profile [17, 19, 21, 24, 25, 27, 41, 42] , including having no effect on the QT or QTc interval [43] .
In the pooled 48-week DUET analysis most AEs in the etravirine group were grade 1 or 2 in severity and, with the exception of rash, were comparable in incidence and frequency to the placebo group (Table 2) . There was a relatively low incidence of discontinuations because of AEs in both the etravirine and placebo treatment groups at 48 weeks (7.2% versus 5.6%, respectively) [27] , and serious AEs also occurred at a similar incidence in the etravirine (19.7%) and placebo (23.3%) groups. Reprinted with permission from [28] . Analysis excludes patients who discontinued for reasons other than virological failure. Numbers at bottom of bars refer to the number of patients in that category (denominator) and the number of patients in that category with viral load <50 copies/ml (numerator [27] . There was no apparent relationship between the pharmacokinetics of etravirine and incidence of AEs or change in laboratory parameters [32] .
Adverse events of interest

Rash
In the pooled 48-week DUET analysis, rash was the only AE to occur significantly more frequently in the etravirine group compared with the placebo group (19.2% versus 10.9%; P<0.0001) [27] .
In the etravirine group, rash events were usually grade 1 or 2 in severity and generally maculopapular in nature, with no mucosal involvement [22] [23] [24] 27, 42] . Rash usually occurred within the first 2 weeks of treatment, with a median duration of 15 days, and tended to resolve on continued treatment [27] . Indeed, after the first 6 weeks of treatment, the incidence of rash was similar between treatment groups and the incidence of new cases of rash remained stable, with new onset of rash reported in <2% of patients [44] . In addition, rash infrequently led to treatment discontinuation, with 2% of patients in the etravirine group discontinuing study medication because of rash by week 48 [27] .
In DUET, although rash with etravirine occurred with a higher incidence in women (30.0%) than in men (18.0%), there were no clear differences in severity or discontinuations between the genders and no relationship with etravirine drug levels or CD4 + T-cell count has been reported [27, 42] .
Although severe and potentially life-threatening skin reactions, including Stevens-Johnson syndrome, hypersensitivity reaction and erythema multiforme, have been reported with etravirine, the incidence of these severe skin reactions is rare (<0.1%) [13] . However, because these reactions can be life-threatening, clinical guidance requires immediate discontinuation of the drug when such severe reactions are suspected. Importantly, a history of NNRTI-related rash was not found to be predictive of etravirine-associated rash events [27] .
Nervous system and psychiatric disorders
Data from the Phase III trials showed that the incidence and severity of nervous system disorders (17.2% and 19.7% for etravirine and placebo, respectively) and psychiatric disorders (16.7% and 19.5%, respectively) were similar across treatment groups [27] . In DUET, these events were generally mild-to-moderate in severity and infrequently led to discontinuations [41] . Among patients receiving etravirine, 0.3% had grade 3 psychiatric disorders, and none had grade 4 psychiatric disorders [39] . Overall, 0.2% of patients in each treatment group discontinued because of psychiatric disorders. Although patients with a psychiatric history displayed an increased frequency of neuropsychiatric events across both treatment arms, the incidences of these events with etravirine were comparable to placebo [24, 25, 41] .
A comparison of neuropsychiatric events in patients switching between etravirine and efavirenz is currently being carried out in a randomized study investigating sleep quality, anxiety and depression (trial number NCT00792584). This is expected to provide valuable data on the differences between the two NNRTIs in their neuropsychiatric side effect profiles.
Hepatic adverse events
Pooled 48-week DUET safety data revealed no evidence of liver toxicity in treatment-experienced patients receiving etravirine. The incidence of hepatic AEs (6.5% versus 6.1%, for etravirine and placebo, respectively) and laboratory hepatic parameters (Table 2) were generally comparable between the etravirine and placebo groups, and mainly grade 1 or 2 in severity [27, 45] . Importantly, the overall incidence of hepatic AEs was similar between treatment groups, irrespective of hepatitis coinfection status [46] .
Lipid abnormalities
Data from the pooled 48-week DUET analysis demonstrated that lipid levels in etravirine-treated patients were generally comparable to the control group (Table 2) . Although lipid abnormalities were difficult to assess in the DUET population, the addition of etravirine to the treatment regimen did not appear to affect lipid-related conditions [27] . Changes in lipid parameters were reported in relatively small proportions of patients, including grade 3 changes in total cholesterol (8.1% etravirine versus 5.3% placebo) and low-density lipoprotein cholesterol (7.2% etravirine versus 6.6% placebo), and grade 3 or 4 changes in triglycerides (9.2% etravirine versus 5.8% placebo).
Reproductive profile
The effect of etravirine on the reproductive system has been investigated in preclinical trials. No teratogenic concerns or any effects on the development of offspring were noted with etravirine [47] . Despite the encouraging preclinical reproductive profile of etravirine, it should be noted that insufficient data are currently available concerning the clinical use of etravirine in pregnancy. Etravirine is currently a pregnancy category B drug. To date, there has been one reported case of successful prevention of mother-to-child transmission in a patient with multidrug-resistant HIV using a regimen of darunavir/ritonavir 600/100 mg twice daily, etravirine 200 mg twice daily, enfuvirtide 90 mg twice daily and tenofovir disoproxil fumarate/emtricitabine 245/200 mg once daily [48] . The patient received the treatment from 25 weeks of gestation and her viral load was fully suppressed (viral load <50 HIV-1 RNA copies/ml) after 1 month. There was evidence of placental transfer of etravirine and darunavir in cord blood samples taken after delivery.
In a case series of five women receiving etravirine in combination with other ARVs during pregnancy (both pre-and post-delivery), no association between etravirine and fetal or neonatal toxicity was observed [49] . In addition, of the patients with available data, three mothers had undetectable HIV-1 RNA at delivery, two babies (twins) were HIV-1-DNA-negative and one baby had undetectable HIV-1 RNA. Further assessment of etravirine in pregnant women is ongoing (trial number NCT00855335).
Virological profile of etravirine Etravirine resistance-associated mutations
Assessments of the virological profile of etravirine have identified a total of 17 etravirine RAMs (V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/ I/V, G190A/S and M230L) [50] . Notably, the frequently observed NNRTI mutation K103N is not associated with resistance or reduced response to etravirine. To assess the differential effect of each RAM on virological response, a weighted genotypic scoring system has been developed [50] . Each etravirine mutation has been assigned a 'relative weight factor' (ranging from 1 to 3; corresponding to low and high effect on virological response; Figure 3A) . These weight factors can be added together to produce a weighted genotypic score, which can be used to predict the response to etravirine. Using this system, etravirine RAMs Y181I and Y181V have the highest relative weights, followed by L100I, K101P, Y181C and M230L. Of the two most common etravirine RAMs in the DUET trials, G190A alone has a weight of 1, associated with the highest virological response, and Y181C alone has a weight of 2.5, associated with an intermediate virological response. NNRTI mutations not on the list of 17 etravirine RAMs have a weight of 0 [50] .
In the DUET studies, a weighted genotypic score of ≤2 has been shown to be associated with a high virological response (viral load <50 HIV-1 RNA copies/ml achieved by 74.4% of patients at week 24), whereas a weighted score from 2.5 to 3.5 is associated with an intermediate virological response (viral load <50 HIV-1 RNA copies/ml achieved in 52.0% of patients at week 24; Figure 3B ).
Importantly, no single RAM (including Y181C) resulted in a reduced virological response to etravirine.
Rather, multiple etravirine RAMs, corresponding to a weighted score ≥4, are required to confer a significantly reduced virological response [50] . These favourable virological attributes of etravirine position it as a treatment option for combination therapy for those patients with NNRTI resistance.
Phenotypic resistance to etravirine
In addition to the weighted genotypic score described above, etravirine resistance data have also provided an opportunity to determine clinical cutoffs (CCOs) for For n values the denominator represents the number of patients with that respective weighted score, the numerator is the number of patients within each group with a viral load <50 copies/ml. Percentages and white boxes behind bars indicate virological response for each category in total. Reprinted from [50] , copyright 2010, with permission from Wolters Kluwer Health.
etravirine [50] . CCOs can be used to provide phenotypic guidance for the use of an ARV agent in treatment-experienced patients and can be used to interpret phenotypic sensitivity by giving an indication, in FC, of how a response to an agent is affected by viral resistance. The lower CCO value defines the FC at which ARV activity will start to decrease and the upper CCO will predict the FC above which there is little or no antiviral activity. Phenotypic CCOs for etravirine are based on pooled week 24 DUET data [50] . A lower CCO of 3 and a preliminary upper CCO of 13 were identified for etravirine. The 'highest' response rate (viral load <50 HIV-1 RNA copies/ml) was observed in patients with baseline etravirine FC≤3 (70.6%). An 'intermediate' response rate (viral load <50 HIV-1 RNA copies/ml) was observed in patients with baseline etravirine FC>3-≤13 (50.0%). An upper CCO, above which patients would no longer benefit from etravirine, could not be determined in this dataset because of the small number of patients with FC>13. Table 3 shows the virological response rates according to phenotypic etravirine CCOs in patients not using enfuvirtide de novo and excluding those who discontinued for reasons other than virological failure before week 24.
Two weighted genotypic scores for predicting response to etravirine -Tibotec scoring system (TBT; Tibotec BVBA, Mechelen, Belgium), which included 17 etravirine RAMs [50] and Monogram scoring system (MGR; Monogram Biosciences, San Francisco, CA, USA), which included 30 etravirine RAMs [51] yielded similar results in treatment-experienced patients [50] . Both scores showed very good concordance in defining sensitivity or resistance to etravirine and association with virological outcome. Among the discordant samples, neither of the two scores was clearly associated with a particular virological outcome. The prediction of response to etravirine using the two scores was also comparable to results obtained using the Stanford genotypic interpretation system (Standford) [50] . The three tested scores effectively predicted virological response with 74.2% (TBT), 73.2% (MGM) and 71.8% (Stanford) of patients with a sensitive score achieving plasma viral load <50 HIV-1 RNA copies/ml at week 24 in DUET. Recently, an independent evaluation of the list of 13 etravirine RAMs (used by the Agence Nationale de Recherche sur le Sida, Paris, France) and the etravirine weighted genotypic scores developed by Tibotec BVBA and Monogram Biosciences was reported using a database containing sequences from treatment-naive and NNRTI-experienced patients [52] . The authors concluded that the weighted scores performed better, especially for samples with partial resistance to etravirine.
The development of the weighted genotypic score and the CCOs described earlier could provide guidance for healthcare professionals when considering whether patients are most likely to benefit from treatment with etravirine.
Dosage and pharmacokinetics of etravirine
Dose and administration
Reduced exposure of etravirine (51%) was observed when etravirine was taken in a fasted state versus following a meal [53] . The type of food has no clinically relevant effect on exposure of etravirine; therefore, etravirine 200 mg (two 100 mg tablets) twice daily should be taken following a meal.
Dispersion of etravirine tablets in water is an option for patients who have difficulty swallowing the tablets. In an open-label, randomized trial involving healthy volunteers, no relevant changes were observed in the oral bioavailability of etravirine when dispersed in water [54] .
Pharmacokinetics
The pharmacokinetics of etravirine have been evaluated in HIV-negative, healthy adult volunteers and in treatment-experienced, HIV-1-infected adult patients. The mean (±sd) population pharmacokinetic estimates of area under the plasma concentration-time curve until 12 h after dosing (AUC 12 h ) and predose concentration (C 0 h ) for etravirine when administered with darunavir/ritonavir 600/100 mg twice daily in 575 treatment-experienced, HIV-1-infected patients was 5,506 (±4,710) ng•h/ml and 393 (±391) ng/ml, respectively [32] .
Two Phase I studies in healthy volunteers compared the pharmacokinetics of twice daily versus once daily etravirine. These studies demonstrated that the daily systemic exposure is similar between these regimens, suggesting that once-daily dosing might be possible [55] . The mean (±sd) AUC 24 h and C 0 h of etravirine 400 mg once daily with tenofovir disoproxil fumarate/ emtricitabine in 21 ARV-naive HIV-1-infected patients was 10,410 (±4,186) ng•h/ml and 250 (±129) ng/ml, respectively. There was no clinically relevant change in etravirine pharmacokinetics with the addition of darunavir/ritonavir 800/100 mg once daily [56] . Further studies of once daily etravirine are ongoing.
An initial investigation into the pharmacokinetics of etravirine in HIV-1-infected children (6-17 years old) showed that 5.2 mg/kg twice daily of etravirine resulted in exposure (AUC 12 h ) of 6,141 ng•h/ml, which was similar to that observed with the 200 mg twice daily dose in adults (5,506 ng•h/ml) [57] . Further evaluation of the pharmacokinetics, safety and tolerability of this dose in children is currently ongoing (trial NCT00665847).
Etravirine is highly bound to albumin (>99.9%) and α 1 -acid glycoprotein (94.5-97.7%), and shows a relatively long half-life of 30-40 h [58] . Etravirine is metabolised by CYP3A, CYP2C9 and CYP2C19 isoenzymes with subsequent glucuronidation of the metabolites [58] . Etravirine and its metabolites are mainly excreted via faeces (93.7%), and renal elimination is negligible (<1.2% of the administered dose of etravirine is excreted in the urine) [59] .
Drug-drug interactions
Etravirine is an inducer of CYP3A and an inhibitor of CYP2C9, 2C19 and P-glycoprotein. The drug-drug interaction profile of etravirine has been investigated in a number of studies [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] , which have shown that it can be coadministered, without dose adjustment, with the majority of ARVs and other medicines commonly taken by HIV-1-infected individuals (Table 4) . Importantly, these include the newer antiretroviral agents (darunavir, raltegravir and maraviroc), which will avoid the addition of further complexity to patients' regimens where these drugs are being used.
Drugs not recommended for coadministration with etravirine include efavirenz, nevirapine, tipranavir/ritonavir, Prescribing information differs in the US and Europe [13, 14] . ARV, antiretroviral; AUC, area under the curve; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; SSRI, selective serotonin reuptake inhibitor.
full-dose (600 mg twice daily) ritonavir, unboosted PIs, rifampin, rifapentine, carbamazepine, phenytoin, phenobarbital and products containing St John's Wort [13] . In addition, clarithromycin is not recommended for the treatment of Mycobacterium avium complex in patients also receiving etravirine, and an alternative anti-infective agent should be considered in such cases.
It should also be noted that there are some regional differences in drug labelling that should be taken into account when prescribing etravirine and local guidelines should be consulted when administering the drug with other agents. For ARVs in particular, this applies to the use of ritonavir-boosted fosamprenavir and atazanavir (both allowed in Europe but not recommended in the US and Canada) and ritonavir-boosted lopinavir (allowed in Europe but recommended with caution in the US and Canada) [13, 14] .
Drugs recommended with caution in combination with etravirine include corticosteroids and immunosuppressants; those requiring dose adjustments or drug monitoring during coadministration include some antiarrhythmics, warfarin, some antifungal agents (for example, ketoconazole), rifabutin, benzodiazepines, sildenafil, lovastatin and simvastatin [13] .
Notably, unlike the first-generation NNRTIs efavirenz and nevirapine, which reduce exposure to methadone and necessitate an increase in methadone dose [71] , etravirine has no clinically relevant pharmacokinetic effects on methadone [72] and can be coadministered without dose adjustment [13] . This might provide an important benefit to some groups of HIV-infected patients who also rely on methadone.
Conclusions
The recent availability of new ARV agents, including etravirine, darunavir, raltegravir and maraviroc for treatment-experienced patients is reminiscent of the clinical effect achieved following the introduction of HAART in the 1990s. Etravirine provides significant and sustained ARV activity in a wide range of treatment-experienced patients, in addition to favourable safety, resistance and pharmacokinetic profiles. The development of etravirine represents a 'new era' for the NNRTI class. It provides a viable treatment option for a broader range of HIV-1-infected patients and expands the use of NNRTIs after previous NNRTI virological failure. Treatment with etravirine in combination with new ARV agents has the capacity to reach unprecedented response rates in treatment-experienced patients. 
